CompletedNCT03859973
BI 425809 and Computer-Based Brain Training for Schizophrenia
About this title
Read the official source — NCT03859973This study evaluated the safety and effectiveness of BI 425809 for people with schizophrenia.
Medication studyAges 18–50Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of BI 425809 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: April 15, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 200
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT03859973
- Official title
Show the full official title
A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Rogers, United States · Encino, United States
46 more locations
- Garden Grove, United States
- Lemon Grove, United States
- Montclair, United States
- Oakland, United States
- Orange, United States
- Pico Rivera, United States
- San Diego, United States
- Torrance, United States
- Maitland, United States
- Miami, United States
- Tallahassee, United States
- West Palm Beach, United States
- Atlanta, United States
- Chicago, United States
- Lake Charles, United States
- Grand Rapids, United States
- Kansas City, United States
- New York, United States
- Raleigh, United States
- Dayton, United States
- Dallas, United States
- Richardson, United States
- Richmond, United States
- Bellevue, United States
- Elizabeth Vale, Australia
- Clayton, Australia
- Fitzroy, Australia
- Melbourne, Australia
- Calgary, Canada
- Vancouver, Canada
- Toronto, Canada
- Montreal, Canada
- Caen, France
- Dijon, France
- Douai, France
- Montpellier, France
- Nantes, France
- Nice, France
- Paris, France
- Saint-Priest-en-Jarez, France
- Takpuna Auckland, New Zealand
- Cheltenham, United Kingdom
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of BI 425809 for people with schizophrenia.
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including BI 425809 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia